Analytic Investors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q3
Sell
-597,711
Closed -$47.1M 639
2016
Q2
$47.1M Sell
597,711
-6,706
-1% -$505K 0.56% 55
2016
Q1
$43.5M Sell
604,417
-78,459
-11% -$5.94M 0.53% 56
2015
Q4
$57.5M Sell
682,876
-272,419
-29% -$22.6M 0.72% 40
2015
Q3
$79.9M Sell
955,295
-434,305
-31% -$36.7M 1.07% 26
2015
Q2
$116M Sell
1,389,600
-664,697
-32% -$50.6M 1.63% 15
2015
Q1
$149M Buy
2,054,297
+404,148
+24% +$28.8M 2.04% 8
2014
Q4
$114M Buy
1,650,149
+208,083
+14% +$14M 1.62% 13
2014
Q3
$93.5M Sell
1,442,066
-85,953
-6% -$5.44M 1.34% 12
2014
Q2
$95M Buy
1,528,019
+365,320
+31% +$21.8M 1.54% 10
2014
Q1
$68.4M Sell
1,162,699
-408,414
-26% -$22.8M 1.04% 25
2013
Q4
$80.1M Buy
1,571,113
+32,330
+2% +$1.62M 1.33% 18
2013
Q3
$77.4M Sell
1,538,783
-340,517
-18% -$17.8M 1.25% 18
2013
Q2
$92.3M Buy
+1,879,300
New +$102M 1.53% 8

Other funds holding LLY

Analytic Investors's LLY Position: Q3 2016 in Review

Analytic Investors sold out of Eli Lilly (LLY) in Q3 2016, closing a stake of 597,711 shares — an estimated $47.1M sold.

Analytic Investors first reported a position in LLY in Q2 2013 and held it in 13 quarters. The position peaked at $149M in Q1 2015. 1,176 funds tracked by Wall St. Rank hold LLY as of Q3 2016.

  • Analytic Investors reported no remaining Eli Lilly position as of Q3 2016 after selling out during the quarter.
  • Analytic Investors sold 597,711 Eli Lilly shares in Q3 2016, an estimated $47.1M.
  • Analytic Investors first reported a position in Eli Lilly in Q2 2013 and held it in 13 quarters.
  • Analytic Investors's Eli Lilly position peaked at $149M in Q1 2015.
  • 1,176 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2016.

Based on Analytic Investors's 13F filing for Q3 2016, filed 14 Nov 2016.